Lyell Immunopharma Management
Management criteria checks 3/4
Lyell Immunopharma's CEO is Lynn Seely, appointed in Dec 2022, has a tenure of 2.42 years. total yearly compensation is $1.50M, comprised of 45.2% salary and 54.8% bonuses, including company stock and options. directly owns 0.059% of the company’s shares, worth $72.62K. The average tenure of the management team and the board of directors is 2.8 years and 4.5 years respectively.
Key information
Lynn Seely
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 45.20% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.06% |
| Management average tenure | 2.8yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth
Oct 25Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Apr 16Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Feb 23
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Nov 09Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher
Aug 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Aug 11Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
Dec 15Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845
Oct 06Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Sep 12News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts
Aug 08Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Apr 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Sep 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$335m |
| Dec 31 2024 | US$1m | US$676k | -US$343m |
| Sep 30 2024 | n/a | n/a | -US$204m |
| Jun 30 2024 | n/a | n/a | -US$210m |
| Mar 31 2024 | n/a | n/a | -US$228m |
| Dec 31 2023 | US$3m | US$650k | -US$235m |
| Sep 30 2023 | n/a | n/a | -US$190m |
| Jun 30 2023 | n/a | n/a | -US$209m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$19m | US$30k | -US$183m |
| Sep 30 2022 | n/a | n/a | -US$258m |
| Jun 30 2022 | n/a | n/a | -US$237m |
| Mar 31 2022 | n/a | n/a | -US$263m |
| Dec 31 2021 | US$5m | n/a | -US$250m |
Compensation vs Market: Lynn's total compensation ($USD1.50M) is above average for companies of similar size in the US market ($USD655.68K).
Compensation vs Earnings: Lynn's compensation has been consistent with company performance over the past year.
CEO
Lynn Seely (65 yo)
Dr. Lynn Seely, MD, Ph D., serves as Lead Independent Director at Blueprint Medicines Corporation since June 2021. She serves as President and Chief Executive Officer at Lyell Immunopharma, Inc. since Dece...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 5.3yrs | US$288.07k | 1.21% $ 1.5m | |
| President | 2.4yrs | US$1.50m | 0.059% $ 72.6k | |
| Chief Operating Officer | 3.5yrs | US$1.34m | 0.0069% $ 8.5k | |
| Advisor | less than a year | US$1.87m | 0% $ 0 | |
| Founder & Scientific Advisor | 2.8yrs | no data | no data | |
| Founder & Scientific Advisor | 2.8yrs | no data | no data | |
| Chief Financial Officer | 4.3yrs | US$4.32m | 0.075% $ 91.4k | |
| Director of Accounting | no data | no data | no data | |
| Chief Scientific Officer | 3.3yrs | US$2.23m | 0.0082% $ 10.0k | |
| Senior Vice President of Communications & Investor Relations | no data | no data | no data | |
| Senior Vice President of Human Resources | 1.8yrs | no data | no data | |
| Senior Vice President of Clinical Development Operations | 1.8yrs | no data | no data |
Experienced Management: LYEL's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 5.3yrs | US$288.07k | 1.21% $ 1.5m | |
| President | 4yrs | US$1.50m | 0.059% $ 72.6k | |
| Independent Director | 6.7yrs | US$262.16k | 0% $ 0 | |
| Independent Director | 5yrs | US$279.89k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$265.34k | 0.012% $ 14.8k | |
| Independent Director | 4.1yrs | US$269.22k | 0% $ 0 | |
| Independent Director | less than a year | US$177.27k | 0.068% $ 83.0k | |
| Lead Independent Director | 6.8yrs | US$307.84k | 0.11% $ 139.6k |
Experienced Board: LYEL's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 10:19 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lyell Immunopharma, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Salveen Richter | Goldman Sachs |
| Mitchell Kapoor | H.C. Wainwright & Co. |